Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
5-Fluoro-3-Pyridinecarboxylic Acid · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| TPF | EXPERIMENTAL | Docetaxel, Cisplatine, 5-FU |
| PF | ACTIVE_COMPARATOR | Cisplatine, 5-FU |
| Name | Type | Description |
|---|---|---|
| DOCETAXEL | DRUG | 75 mg/m 2 on day 1 |
| Cisplatin | DRUG | 75 mg/m 2 on day 1 |
| 5-Fluoro-3-Pyridinecarboxylic Acid | DRUG | 750 mg/m 2 by 24-hour continuous infusion for 5 days |
Inclusion Criteria: * T3 and T4 larynx and hypopharynx tumor that would be treated with total laryngectomy * Biopsy proven carcinoma * Adequate biology * Performance status 0 or 1 Exclusion Criteria: * Larynx or hypopharynx tumors that could be treated with partial laryngectomy * Distant metastas...
5-Fluoro-3-Pyridinecarboxylic Acid is an investigational small molecule being studied for the treatment of larynx cancer, specifically in patients with T3 and T4 larynx and hypopharynx carcinoma. It is being evaluated in combination with cisplatin and with or without docetaxel as induction chemotherapy.
Sanofi (ticker: SNY) is the developer of 5-Fluoro-3-Pyridinecarboxylic Acid. The company is conducting clinical research on this investigational small molecule for the treatment of larynx cancer.
5-Fluoro-3-Pyridinecarboxylic Acid is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 3 trial has been completed.
5-Fluoro-3-Pyridinecarboxylic Acid has one completed Phase 3 trial, NCT00169182, titled "Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma." The trial enrolled 220 participants in France and included patients aged 18 years and older.
5-Fluoro-3-Pyridinecarboxylic Acid is a fluorinated pyridine carboxylic acid derivative. It is being studied in combination with cisplatin and docetaxel for larynx cancer. The drug is distinct from 5-fluorouracil (5-FU), which is a separate chemotherapy agent.